- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
EGFR+ Lung Cancer | Clinical
Barriers of Treating EGFR-Mutant NSCLC With Adjuvant Osimertinib
July 23, 2021
Nathan Pennell, MD, PhD, discusses the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer.
Precise Management of EGFR exon 20-Positive Non–Small Cell Lung Cancer
July 21, 2021
Research shows that methods used to treat the wide epidermal growth factor receptor-positive population are often not successful for patients with specific biomarkers like EGFR exon 20 insertion mutations, highlighting an ongoing need for more targeted therapies.
Efficacy and Feasibility of Neoadjuvant Osimertinib Demonstrated in Early-Stage EGFR+ Lung Adenocarcinoma
July 13, 2021
Neoadjuvant osimertinib is effective and feasible for use as treatment for patients with stage II-IIIB EGFR-mutant lung adenocarcinoma, according to interim analysis results of the NEOS study.
High BMI Negatively Impacts Survival Outcomes With Osimertinib in EGFR+ NSCLC
July 05, 2021
In a retrospective analysis of patients with advanced non–small cell lung cancer and EGFR mutations treated with osimertinib, investigators found that body mass index of 25 kg/mq2 or more had a negative impact on survival outcomes.
The Standard of Care for EGFR Exon 20 Insertion+ Lung Cancer
June 23, 2021
Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the current standard of care for EGFR exon 20 insertion-mutated lung cancer.
The Growing Armamentarium Against EGFR Exon 20+ Non–Small Cell Lung Cancer
June 10, 2021
Joshua K. Sabari, MD, reviews the therapies available to treat patients with EGFR exon 20-positive non–small cell lung cancer.
Gefitnib Delays Early Relapse, Fails to Improve DFS or OS Compared to Chemotherapy in EGFR-mutant NSCLC
June 06, 2021
New data from the phase 3 IMPACT trial shows the advantages and shortcomings of gefitinib in patients with EGFR-mutant non-small cell lung cancer.
The Safety Profile of Amivantamab and Lazertinib in EGFR-Mutant NSCLC
June 06, 2021
Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the safety profile of amivantamab and lazertinib in EGFR-mutated non-small cell lung cancer, based on data from the CHRYSALIS tria.
Aumolertinib Extends PFS and Duration of Response in EGFR+ Non–Small Cell Lung Cancer
June 05, 2021
Treatment with aumolertinib led to improved progression free survival and duration of response in patients with advanced non-small cell lung caner with epidermal growth factor receptor, compared with gefitinib.
Patritumab Deruxtecan Demonstrates Durable Efficacy in Heavily-Pretreated EGFR+ NSCLC Subset
June 05, 2021
treatment with patritumab deruxtecan induced clinically meaningful, durable efficacy in heavily pretreated patients with EGFR-mutated non–small cell lung cancer who were resistant to EGFR tyrosine kinase inhibitors.